Effectiveness of Platelet-Rich Fibrin for Temporomandibular Disorders Management: A Systematic and Meta-Analysis.

IF 2.9 3区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral diseases Pub Date : 2025-09-07 DOI:10.1111/odi.70089

Júlia Silva Gomes de Araújo, Wellington Luiz de Oliveira da Rosa, Luiz Augusto Duarte Meirelles, Mateus Gaya Dos Santos, Noéli Boscato

{"title":"Effectiveness of Platelet-Rich Fibrin for Temporomandibular Disorders Management: A Systematic and Meta-Analysis.","authors":"Júlia Silva Gomes de Araújo, Wellington Luiz de Oliveira da Rosa, Luiz Augusto Duarte Meirelles, Mateus Gaya Dos Santos, Noéli Boscato","doi":"10.1111/odi.70089","DOIUrl":null,"url":null,"abstract":"Objective: This study systematically reviewed the effect of intra-articular injection (IAI) of platelet-rich fibrin (i-PRF), alone or combined with arthrocentesis or arthroscopy, in managing painful articular temporomandibular disorders (TMD) and improving maximum mouth opening (MMO).Materials and methods: A systematic literature search was conducted in five databases, identifying randomized and nonrandomized clinical trials focusing on minimally invasive TMJ interventions using i-PRF. Meta-analyses were performed with a random-effects model for studies reporting similar outcomes, visual analog scale (VAS) scores for pain, and MMO values.Results: Out of 332 studies identified, 13 met the inclusion criteria for meta-analysis. Within-group comparisons revealed significant pain reduction at 3-6 and 8-12 months for i-PRF alone or combined with arthrocentesis or arthroscopy. MMO values significantly increased using i-PRF alone at 8-12 months, combined with arthrocentesis or arthroscopy at 3-6 and 8-12 months, with no significant increase using i-PRF alone at 3-6 months. Between-group analyses demonstrated that i-PRF combined with arthrocentesis significantly reduced VAS scores and increased MMO values compared to arthrocentesis alone at 3-6 and 8-12 months.Conclusion: Using i-PRF alone or combined with arthrocentesis or arthroscopy is effective in pain reduction and MMO increase.","PeriodicalId":19615,"journal":{"name":"Oral diseases","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/odi.70089","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study systematically reviewed the effect of intra-articular injection (IAI) of platelet-rich fibrin (i-PRF), alone or combined with arthrocentesis or arthroscopy, in managing painful articular temporomandibular disorders (TMD) and improving maximum mouth opening (MMO).

Materials and methods: A systematic literature search was conducted in five databases, identifying randomized and nonrandomized clinical trials focusing on minimally invasive TMJ interventions using i-PRF. Meta-analyses were performed with a random-effects model for studies reporting similar outcomes, visual analog scale (VAS) scores for pain, and MMO values.

Results: Out of 332 studies identified, 13 met the inclusion criteria for meta-analysis. Within-group comparisons revealed significant pain reduction at 3-6 and 8-12 months for i-PRF alone or combined with arthrocentesis or arthroscopy. MMO values significantly increased using i-PRF alone at 8-12 months, combined with arthrocentesis or arthroscopy at 3-6 and 8-12 months, with no significant increase using i-PRF alone at 3-6 months. Between-group analyses demonstrated that i-PRF combined with arthrocentesis significantly reduced VAS scores and increased MMO values compared to arthrocentesis alone at 3-6 and 8-12 months.

Conclusion: Using i-PRF alone or combined with arthrocentesis or arthroscopy is effective in pain reduction and MMO increase.

查看原文本刊更多论文

富血小板纤维蛋白治疗颞下颌疾病的有效性：一项系统荟萃分析。

目的：本研究系统回顾了关节内注射（IAI）富血小板纤维蛋白（i-PRF），单独或联合关节穿刺或关节镜治疗疼痛性关节颞下颌紊乱（TMD）和改善最大开口（MMO）的效果。材料和方法：对5个数据库进行系统的文献检索，确定采用i-PRF微创TMJ干预的随机和非随机临床试验。采用随机效应模型对报告相似结果的研究、疼痛的视觉模拟量表（VAS）评分和MMO值进行meta分析。结果：在确定的332项研究中，13项符合meta分析的纳入标准。组内比较显示单独使用i-PRF或联合关节穿刺或关节镜治疗3-6个月和8-12个月疼痛明显减轻。单独使用i-PRF在8-12个月时，联合关节穿刺或关节镜在3-6个月和8-12个月时，MMO值显著增加，单独使用i-PRF在3-6个月时无显著增加。组间分析显示，在3-6个月和8-12个月时，与单纯关节穿刺相比，i-PRF联合关节穿刺显著降低了VAS评分，增加了MMO值。结论：i-PRF单用或联合关节穿刺或关节镜检查均能有效减轻疼痛，增加MMO。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral diseases 医学-牙科与口腔外科

CiteScore

7.60

自引率

5.30%

发文量

325

审稿时长

4-8 weeks

期刊介绍： Oral Diseases is a multidisciplinary and international journal with a focus on head and neck disorders, edited by leaders in the field, Professor Giovanni Lodi (Editor-in-Chief, Milan, Italy), Professor Stefano Petti (Deputy Editor, Rome, Italy) and Associate Professor Gulshan Sunavala-Dossabhoy (Deputy Editor, Shreveport, LA, USA). The journal is pre-eminent in oral medicine. Oral Diseases specifically strives to link often-isolated areas of dentistry and medicine through broad-based scholarship that includes well-designed and controlled clinical research, analytical epidemiology, and the translation of basic science in pre-clinical studies. The journal typically publishes articles relevant to many related medical specialties including especially dermatology, gastroenterology, hematology, immunology, infectious diseases, neuropsychiatry, oncology and otolaryngology. The essential requirement is that all submitted research is hypothesis-driven, with significant positive and negative results both welcomed. Equal publication emphasis is placed on etiology, pathogenesis, diagnosis, prevention and treatment.